PPC
PCVX icon

Park Place Capital’s Vaxcyte PCVX Stock Holding History

Park Place Capital’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16
Closed -$576 – 830
2025
Q3 		$576 Hold
16
– – ﹤0.01% 775
2025
Q2 		$527 Hold
16
– – ﹤0.01% 793
2025
Q1 		$604 Buy
+16
New +$1.28K ﹤0.01% 805

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Park Place Capital's PCVX Position: Q4 2025 in Review

Park Place Capital sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 16 shares — an estimated $576 sold.

Park Place Capital first reported a position in PCVX in Q1 2025 and held it in 3 quarters. The position peaked at $604 in Q1 2025. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

  • Park Place Capital reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
  • Park Place Capital sold 16 Vaxcyte shares in Q4 2025, an estimated $576.
  • Park Place Capital first reported a position in Vaxcyte in Q1 2025 and held it in 3 quarters.
  • Park Place Capital's Vaxcyte position peaked at $604 in Q1 2025.
  • 295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Park Place Capital's 13F filing for Q4 2025, filed 9 Jan 2026.